Impact of Epidermal Growth Factor Receptor Expression on Disease-Free Survival and Rate of Pelvic Relapse in Patients With Advanced Cancer of the Cervix Treated With Chemoradiotherapy
Authors:
- Alfonso Sánchez-MuñozASAlfonso Sánchez-Muñoz
- Javier De-La-CruzJDJavier De-La-Cruz
- Claudio BallestínCBClaudio Ballestín
- David LoraDLDavid Lora
- Rosa García-MartínRGRosa García-Martín
- Amalia SotocaASAmalia Sotoca
- Elisabeth Pérez-RuizEPElisabeth Pérez-Ruiz
- Eduardo LanzósELEduardo Lanzós
- 1 August 2011
- journal article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 34 (4) , 395-400
Abstract
To determine the impact of the expression of epidermal growth factor receptor (EGFR) on disease-free survival (DFS) and on pelvic relapse in patients with advanced cancer of the cervix receiving concurrent chemoradiotherapy. In 112 consecutive patients with advanced cancer of the cervix (11 stage IB2-IIA, 25 IIB, 63 IIIB, 13 IVA) treated with chemoradiotherapy between December 1994 and September 2004, the expression of EGFR using histoimmunochemistry was measured and used in univariate and multivariate analysis, along with variables such as age, International Federation of Gynecology and Obstetrics Staging System for Epithelial Ovarian Cancer (FIGO) stage, histology, Eastern Cooperative Oncology Group (ECOG), tumor size, and ganglia involvement diagnosed with computerized axial tomography, treatment with cisplatin to evaluate its impact on DFS and pelvic relapse. Of the 112 biopsies, 32 (28.6%) were negative or slightly positive (EGFR±) and 80 (71.4%) were moderate or intensely positive (EGFR++/+++). The overexpression of EGFR (++/+++) was significantly associated with an epidermoid histology (P < 0.0001), with a higher rate of pelvis relapse and a decreased DFS (hazard ratio [HR]: 2.31 [1.08-4.96]; P = 0.03). Overall, treatment with cisplatin increased DFS (HR: 0.51 [0.26-0.97]; P = 0.04). Patients with tumors of the cervix and overexpression of the EGFR++/+++ show a higher probability of pelvic relapses and a decreased disease-free survival. The poor prognosis of these tumors may be a consequence of an increase in radio-resistance.Keywords
This publication has 30 references indexed in Scilit:
- Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysisGynecologic Oncology, 2004
- Pelvic Irradiation With Concurrent Chemotherapy Versus Pelvic and Para-Aortic Irradiation for High-Risk Cervical Cancer: An Update of Radiation Therapy Oncology Group Trial (RTOG) 90-01Journal of Clinical Oncology, 2004
- Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression?The Oncologist, 2002
- Expression of cathepsin D and epidermal growth factor receptor in stage III cervical carcinomasInternational Journal of Gynecological Cancer, 1997
- Expression of Epidermal Growth Factor Receptor in Carcinoma of the CervixGynecologic Oncology, 1996
- Epidermal growth factor-related peptides and their receptors in human malignanciesCritical Reviews in Oncology/Hematology, 1995
- Prognostic factors in patients with cervix cancer treated by radiation therapy: results of a multiple regression analysisRadiotherapy and Oncology, 1995
- Expression of ras oncogene product and EGF receptor in cervical squamous cell carcinomas and its relationship to lymph node involvementGynecologic Oncology, 1991
- Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: A Gynecologic Oncology Group studyGynecologic Oncology, 1990
- Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervixGynecologic Oncology, 1989